컬리넌 온콜로지(CGEM)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $20.73 (-2.95%), 시가총액 $0.84B, 52주 최저~최고 $5.75 ~ $16.33.
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibi
컬리넌 온콜로지의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
컬리넌 온콜로지의 현재 주가는 $20.73 (-2.95%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
컬리넌 온콜로지의 시가총액은 약 $0.84B입니다.
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD